Vanderbilt Vaccine Center

Early study finds antibody that ‘neutralizes’ Zika virus

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

Preparing for a return of pox

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.

knight with sword and shield

Research sheds light on how RSV wards off potential vaccines

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.

drawing of trojan horse

Investigators create ‘Trojan Horse’ to fight Ebola

A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.

goofy toy disguise

Research team takes aim at Ebola virus ‘decoy protein’

Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.

Influx of major NIH grants fuels growth of research enterprise

During the past two weeks, researchers at Vanderbilt University and Vanderbilt University Medical Center (VUMC) have brought in a number of new research grants from the National Institutes of Health (NIH) that together achieve $137 million in new funding. The funding is a trans-institutional accomplishment of the Schools of Engineering and Medicine and the College of Arts and Science.

1 7 8 9 10 11 14